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TO THE EDITOR
Chronic myelogenous leukemia is characterized by a reciprocal translocation, t(9;22)(q34;q11), between the long arms of chromosomes 9 and 22, leading to the Philadelphia chromosome. Two fusion genes are created by this translocation: bcr/abl and abl/bcr. The fusion regions of both translocation products are unique and strictly limited to leukemia cells, giving rise to potential tumor-specific antigens.
Current treatment options for CML include stem cell transplantation, and hydroxyurea-based or interferon-␣-based regimens. 1 Much attention has been focused recently on the newly introduced tyrosine kinase inhibitor STI571 with its striking effect in almost all patients. However, resistance to STI571 as a single agent occurs frequently and rapidly, and allogeneic stem cell transplantation is still regarded as the only curative treatment for CML. The latter is thought to depend on a T cell-mediated graft-versus-leukemia effect (GVL) distinct from the graft-versus-host effect, suggesting specific recognition of tumor cells by the immune system. This effect may also be achieved by administration of donor leukocyte infusions after relapse in transplant recipients. Although GVL is largely caused by differences in major and minor histocompatibility antigens between donor and recipient, there is also evidence for leukemia-specific recognition. Vaccination with tumor-specific antigens could enhance or initiate antileukemic effects. 2 However, little is known about the nature of such potential CMLspecific tumor antigens. Research has focused on the Bcr/Abl proteins, known to cause the disease. Whereas several studies on the immunogenicity of peptides spanning the fusion region of bcr/abl have appeared, nothing is known about the corresponding reciprocal translocation product abl/bcr, the expression of which can be detected at the mRNA level in the majority of CML patients. Depending on the location of the breakpoint, different isoforms are present: a1b-b3 or a1a-b3 corresponding to the b2a2 fusion and a1b-b4 or a1a-b4 corresponding to the b3a2 fusion. Previous studies have shown that the a1bb3 and a1bb4 transcripts predominate, and that a1ab3 and a1ab4 are expressed only rarely and then always together with the a1b forms. 3 Several peptides derived from the fusion region of the abl/bcr product have been shown to bind to HLA class I molecules in vitro. 4 To investigate the potential immunogenicity of the abl/bcr fusion region, we selected two strongly HLA-A2 binding peptide sequences, comprising the a1bb3 (FVEHDDESPGL) and a1bb4 (FVEHDLYCTL) fusion region respectively, and attempted to sensitize T cells of healthy HLA-A2-positive donors in vitro against them. Autologous dendritic cells were generated from peripheral blood monocytes by in vitro culture with GM-CSF and IL-4. After TNF␣-induced maturation, DC were pulsed with the respective peptide and used as APC in the priming. T cell cultures were restimulated weekly with irradiated peptidepulsed T2 cells. After two rounds of restimulation, IL-2 was added 1 day after the restimulation. After six to eight restimulations, T cell cultures were tested for peptide-specific cytotoxicity. At that time T cell cultures were Ͼ95% CD3-positive, Ͼ80% CD8-positive, Ͻ20% CD4-positive and Ͻ1% CD56-positive as detected by flow cytometry prior to specificity testing. From two of the four donors tested, we obtained T cell lines recognizing the sensitizing peptides.
T cell lines B360 and B363, derived from two different donors sensitized against the a1bb3 peptide, lysed T2 cells pulsed with the a1bb3 peptide but not T2 cells pulsed with an HLA-A2-binding control peptide ( Figure 1a ). This showed that these T cell lines specifically recognize the a1bb3 peptide presented by HLA-A2 molecules on T2 cells. For the a1bb4 peptide, we also obtained two T cell lines from different donors, designated B460 and B463, specifically recognizing a1bb4 ( Figure 1b ). NK cell activity was excluded in all cases as none of these T cell lines lysed the NK cell target K562 in concurrent experiments. The experiments were repeated with the same cells on different occasions with similar results. Thus, synthetic peptides derived from the fusion region of a1bb3 as well as a1bb4 not only bind to HLA-A2 molecules, but these peptide-MHC complexes can be recognized specifically by peripheral CD8 + T cells from healthy donors. Having demonstrated the immunogenicity of these synthetic abl/bcr peptides, it was important to establish whether the peptide-reactive cell lines would also be able to recognize native CML cells. Abl/bcr + cells from two chronic-phase HLA-A*0201 + CML patients were chosen as target cells. CML8 showed a1bb4 expression whereas CML9 expressed a1bb3. Instead of the weekly restimulation with T2 cells, 1 × 10 6 T cells of each peptide-specific line were incubated with 1 × 10 6 CML cells. After 24 h supernatants were harvested, and tested for TNF␣ content by a standard ELISA. The T cell lines B360 and B363, specific for the a1bb3 fusion peptide, reacted with strong TNF␣ secretion to the a1bb3 
cells. Recognition of a1bb3
+ CML cells, but not a1bb4 + CML cells by a1bb3-specific CTL strongly suggest intracellular processing of abl/bcr protein and presentation by HLA-A2 molecules. The abl/bcr fusion is highly specific for and widely expressed in CML and abl/bcr proteins therefore represent novel shared tumor-specific antigens. The few molecular studies of abl/bcr indicated no obvious essential role in the occurrence and course of CML. This, together with the fact that the presence of an abl/bcr protein has not yet been reported, might explain why abl/bcr has been neglected as a potential tumor antigen to date. But even if the abl/bcr protein may be misfolded and rapidly degraded without performing a cellular function, it may well be processed and presented by HLA molecules. The recognition of CML cells by abl/bcr peptide-specific T cells is indeed indirect evidence for translation of abl/bcr message.
Large deletions on the derivative chromosome 9, adjacent to the breakpoint, ie the abl/bcr fusion gene, have been reported and were associated with a more rapid onset of blast crisis. 5 The frequency of the deletion was similar at diagnosis and after disease progression, indicating it may be an early event in tumor development. It is tempting to speculate that recognition of abl/bcr by T cells is effective at early stages of tumorigenesis and that neoplastic cells must find ways to circumvent this immune attack. One mechanism would be the loss of abl/bcr expression. Even if abl/bcr expression does not correlate strongly with the 9q+ deletion or survival in CML, this might be explained by other tumor escape mechanisms, eg anergy induction in abl/bcr-specific T cells.
Thus far, only a small number of class-I restricted tumor antigens has been described for CML. Most research has focused on bcr/abl, where several different epitopes for different HLA alleles have been described. While direct recognition of CML cells could not be observed in all studies, endogenous presentation of bcr/abl peptide by HLA-A3 molecules on CML cells has been recently convincingly demonstrated. 6 There are a few reports of other CML antigens, eg proteinase 3 has been shown to be a leukemia-associated antigen, and WT-1 may also fall into this category. 7 Defined class-II restricted CMLspecific antigens are limited to bcr/abl epitopes. Several HLA-DR alleles have been shown to present bcr/abl peptides and elicit CD4 + T helper cell responses. 8 Direct recognition of CML cells by bcr/ablspecific T cells could only be shown in a minority of cases. However, direct recognition of CML cells by CD4 + T cells may not play an important role, as evidence is accumulating that the major role of T helper cells in tumor immunity is not direct recognition of tumor cells itself, but rather to provide help to professional APC during 'crosspriming'.
The presence of T cells capable of recognizing abl/bcr on the CML cell surface in the T cell pool of healthy donors makes it likely that such T cells may also exist, albeit perhaps in an anergic state, in CML patients. There is evidence that leukemia-reactive T cells while not clonally deleted in CML patients, may be tolerized in vivo. This tolerance may be abrogated in vitro and by implication in vivo to reveal CML-specific responses. Therefore, it remains attractive to enhance or initiate anti-leukemic-specific immune responses by vaccination with known tumor antigens. Abl/bcr-derived peptides could be profitably combined with bcr/abl in this approach.
Increased caspase-3 activity in refractory anemias: lack of evidence for Fas pathway implication The myelodysplastic syndromes (MDS) are characterized by ineffective hematopoiesis, peripheral blood cytopenias and abnormal growth of marrow committed progenitor cells. In line with the apparent contradiction between a frequently increased marrow cellularity and peripheral cytopenias, it has been hypothesized that the functional bone marrow failure is due to premature intramedullary cell death by apoptosis. We recently described an increased activation of cysteine proteases (caspases), particularly the major effector protein of the programmed cell death caspase-3, which was readily inhibited by a specific caspase inhibitor Ac-DEVD-CHO. This was especially observed in refractory anemia (RA) and RA with ringed sideroblasts (RARS), 1 Others studies have shown that MDS bone marrow mononuclear cells or CD34+ cells strongly expressed Fas and Fas-L as compared to cells of normal individuals. 2, 3 Signaling through Fas requires the formation of a death-inducing signaling complex (DISC) that involves the cyto- Caspase activity expressed in pmoles/min/mg of proteins is assessed in the S100 cytosolic fraction extract of bone marrow mononuclear cells (BMMNC).
